Amicus Therapeutics (FOLD) to Release Quarterly Earnings on Wednesday

Amicus Therapeutics (NASDAQ:FOLD) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $147.88 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Amicus Therapeutics Price Performance

FOLD opened at $9.85 on Wednesday. The firm has a market cap of $2.94 billion, a P/E ratio of -28.97, a PEG ratio of 1.69 and a beta of 0.61. The firm has a 50-day moving average of $9.60 and a 200 day moving average of $10.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $14.02.

Wall Street Analysts Forecast Growth

FOLD has been the subject of several research reports. Guggenheim increased their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, JPMorgan Chase & Co. increased their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $16.88.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.